[Manipulation of genes causing diseases].
The intervention on specific genes causing diseases in mammals as in humans is nowadays feasible. Technology has allowed the expression of a correct gene introduced to a cell or to inhibit the expression of an undesirable gene. This opens therapeutic possibilities for a great assortment of diseases, from genetic errors of metabolism to AIDS. The assays performed have been scarce, mainly due to fears on possible collateral effects. The National Institutes of Health has required to present the protocol for analysis and approval to a committee of 20 people, for every proposal of clinical trial. Only 100 clinical trials in catastrophic or incurable diseases have been approved. Up to now, the rate of complications has been low and the approval of a greater amount of clinical trials is expected in the near future.
Monckeberg
F
F
Universidad Santo Tomás, Santiago de Chile.
D000243:Adenosine Deaminase / Q000172:deficiency / Q000235:genetics; D000818:Animals; D002986:Clinical Trials as Topic; D003550:Cystic Fibrosis / Q000235:genetics; D005069:Evaluation Studies as Topic; D015870:Gene Expression; D005818:Genetic Engineering; D015316:Genetic Therapy; D005822:Genetic Vectors; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000235:genetics; D009369:Neoplasms / Q000235:genetics; D010957:Plasmids; D012107:Research Design; D017086:beta-Thalassemia / Q000235:genetics
D000243:Adenosine Deaminase